Short answer
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an 8-K current report with the SEC on March 5, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Board expanded to 10 directors; Christopher Gibson, Ph.D. appointed Class I director effective March 3, 2026.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded to 10 directors; Christopher Gibson, Ph.D. appointed Class I director effective March 3, 2026
- Gibson assigned to Science and Technology Committee: signals focus on scientific/R&D credibility for PACB's genomics platform
- Compensation per standard non-employee director policy detailed in April 23, 2025 proxy statement
- No related-party transactions or undisclosed arrangements: clean appointment with no governance concerns flagged
Item 7.01 · Regulation FD Disclosure
- Dr. Gibson appointed to a key role at Pacific Biosciences, announced via press release dated March 5, 2026
- Leadership change potentially signals strategic or scientific direction shift: full terms in Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 8-K filings
Get the next PACB 8-K as it lands
Follow PACB for push alerts, or ask the research agent what this filing means.